AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by WCM Investment Management LLC

WCM Investment Management LLC lessened its stake in AtriCure, Inc. (NASDAQ:ATRC) by 11.0% in the fourth quarter, Holdings Channel reports. The fund owned 191,801 shares of the medical device company’s stock after selling 23,785 shares during the quarter. WCM Investment Management LLC’s holdings in AtriCure were worth $5,802,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its stake in shares of AtriCure by 151.6% in the third quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock valued at $6,425,000 after purchasing an additional 138,046 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in AtriCure by 31.5% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock valued at $14,038,000 after buying an additional 119,929 shares during the last quarter. Champlain Investment Partners LLC grew its stake in shares of AtriCure by 4.3% during the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock valued at $78,253,000 after acquiring an additional 115,813 shares in the last quarter. Two Sigma Advisers LP increased its holdings in AtriCure by 14.6% during the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock worth $18,621,000 after purchasing an additional 84,700 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of AtriCure in the third quarter worth $1,991,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

ATRC has been the subject of several research analyst reports. UBS Group upped their price objective on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of AtriCure in a report on Tuesday, December 17th. Needham & Company LLC increased their target price on shares of AtriCure from $40.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Canaccord Genuity Group lifted their price target on shares of AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Oppenheimer increased their price objective on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.38.

AtriCure Price Performance

NASDAQ ATRC opened at $41.00 on Monday. The company has a 50-day moving average price of $35.19 and a two-hundred day moving average price of $30.78. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -49.40 and a beta of 1.46. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.